Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in the treatment of muscle-invasive bladder cancer.

Trial Details

NCT ID
NCT06686381
Phase
PHASE2
Sponsor
American University of Beirut Medical Center
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Maximum TURBT
  • Chemotherapy + Immunotherapy Induction
  • Radiotherapy
  • Immunotherapy Maintenance
  • Watchful waiting with supportive care
Locations (sample)
  • Beirut, Beirut, Lebanon|33.89332,35.50157

Key Eligibility Criteria

  • Provision of signed and dated informed consent form (ICF) before any trial related procedures.
  • Male or female participant with ≥ 18 years of age at time of consenting.
  • Participant is able and willing to comply with the requirements of trial protocol.
  • Pathologically (histologically or cytologically) and radiologically confirmed newly diagnosed MIBC (T2-T4 N0 M0) or recurrent previously NMIBC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →